Client News

Sun Seems to Be Shining on Solar as Costs Continue to Decline – Wins for Correlate Energy (OTCQB:CIPI) in 2023, and Its Plans for 2024

SHREVEPORT, LA / ACCESSWIRE / March 26, 2024 / The sun may be starting to shine on solar energy as consumers and businesses look for cheaper and cleaner power sources. The sector is expected to continue to grow as the cost of solar energy continues to decline. That’s good news for solar companies like Correlate Energy Corp. (OTCQB:CIPI). The distributed […]

SinglePoint Inc. (CBOE:SING) Provides Corporate Update on Boston Solar Commercial Solar Division Accelerating to Near-Term Operational Profitability and Continued Revenue Growth

PHOENIX, March 26, 2024 /PRNewswire/ — SinglePoint Inc. (CBOE:SING) (“SinglePoint”), an innovative solar energy company, provides shareholders a recap of significant corporate refinements designed to drive operational profitability while maintaining scalability. SinglePoint Inc $SING color logo Recent Corporate Refinements at Boston Solar SinglePoint acquired the remaining interests in Boston Solar in Q1 2024, further solidifying its presence […]

1847 Holdings (NYSE American:EFSH) Request for Withdrawal of Registration Statement on Form S-3

NEW YORK, NY / ACCESSWIRE / March 26, 2024 / 1847 Holdings LLC (“1847” or the “Company”) (NYSE American:EFSH), a holding company specializing in identifying over-looked, deep value investment opportunities in middle market businesses, filed a Request for Withdrawal with the SEC on March 22, 2024 relating to withdrawal of the Company’s Registration Statement on Form […]

NKGen Biotech (Nasdaq: NKGN) Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients. The additional Phase 1 SNK01 trial data suggest clinical activity regarding cognitive function in patients with advanced Alzheimer’s disease in addition to previously disclosed positive effects on amyloid protein and neuroinflammation biomarkers. SANTA ANA, […]

OKYO Pharma (NASDAQ: OKYO) Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial. Conjunctival Staining improved as early as day 29 with a durable benefit throughout the trial. Tear Film Break-up Time showed statistically significant improvement as early as day 15 with the benefit durable for the remainder […]

Q4 2023 Sadot Group Inc (NASDAQ: SDOT) Earnings Call

Participants Frank Pogubila; IR; Sadot Group, Inc. Michael Roper; CEO; Sadot Group, Inc. Jennifer Black; CFO; Sadot Group, Inc. Benjamin Petel; Director; Sadot Group, Inc. Aaron Grey; Analyst; Alliance Global Partners Tom Kerr; Analyst; Zacks Small Cap Research Presentation Operator Welcome to the second Group, Inc. Q4 fiscal year 2023 earnings conference call. Today’s call […]

BYND Cannasoft Enterprises Inc. (Nasdaq:BCAN) Announces 1-for-190 Reverse Stock Split Implemented

Vancouver, British Columbia –News Direct– BYND Cannasoft Enterprises ASHKELON, Israel and VANCOUVER, British Columbia – TheNewswire – March 22, 2024 – BYND Cannasoft Enterprises Inc. (Nasdaq:BCAN) (“BYND Cannasoft” or the “Company”) an Israeli-based integrated software and cannabis company, today announced that the previously announced 1-for-190 reverse stock split of its outstanding shares of common stock […]

OKYO Pharma (NASDAQ: OKYO) to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

–Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease […]

Start Expanding
Your Shareholder Base

Let us help you connect with investors
committed to your success.